We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
-1.01%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
(-9.3%)
Cap. Flow
+$100M
Cap. Flow
% of AUM
2.31%
Top 10 Holdings %
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$183M |
| 2 |
argenx
ARGX
|
+$128M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$108M |
| 4 |
Johnson & Johnson
JNJ
|
+$97.3M |
| 5 |
Humana
HUM
|
+$95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$194M |
| 2 |
Baxter International
BAX
|
+$149M |
| 3 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$146M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$115M |
| 5 |
AbbVie
ABBV
|
+$109M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.61% |
| 2 | Miscellaneous | 3.74% |
| 3 | Financials | 0.54% |
| 4 | Technology | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Jazz Pharmaceuticals
JAZZ
$13.6B
| $9.67M | 0.22% |
+62,000
| New | +$9.54M |
2022 Q2
0 quarters
|
|
52
DELISTED
Alpine Immune Sciences Inc
ALPN
| $8.5M | 0.2% |
998,565
-208,435
| -17% | -$1.8M |
2020 Q3
7 quarters
|
|
53
DELISTED
ESSA Pharma
EPIX
| $7.75M | 0.18% |
2,460,000
| – | – |
2020 Q3
7 quarters
|
|
54
Century Therapeutics
IPSC
$248M
| $7.27M | 0.17% |
865,000
| – | – |
2021 Q2
4 quarters
|
|
55
Erasca
ERAS
$4.68B
| $5.54M | 0.13% |
995,000
| – | – |
2022 Q1
1 quarter
|
|
|
CYT
56
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $5.53M | 0.13% |
1,850,000
| – | – |
2021 Q2
4 quarters
|
|
57
AN2 Therapeutics
ANTX
$128M
| $5.33M | 0.12% |
688,330
| – | – |
2022 Q1
1 quarter
|
|
58
Compass Therapeutics
CMPX
$155M
| $5.3M | 0.12% |
2,000,000
| – | – |
2021 Q4
2 quarters
|
|
|
MSAC
59
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $5.09M | 0.12% |
520,000
| – | – |
2021 Q2
4 quarters
|
|
|
BLSA
60
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $4.95M | 0.11% |
500,000
| – | – |
2020 Q4
6 quarters
|
|
61
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $4.91M | 0.11% |
500,000
| – | – |
2021 Q1
5 quarters
|
|
|
PANA
62
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| $4.88M | 0.11% |
500,000
| – | – |
2021 Q2
4 quarters
|
|
63
SentinelOne
S
$7.51B
| $4.77M | 0.11% |
204,500
| – | – |
2021 Q2
4 quarters
|
|
|
ISEE
64
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.14M | 0.1% |
430,117
-6,045,283
| -93% | -$75.9M |
2021 Q2
4 quarters
|
|
65
Orchestra BioMed
OBIO
$328M
| $3.98M | 0.09% |
400,000
| – | – |
2020 Q3
7 quarters
|
|
66
Tango Therapeutics
TNGX
$3.72B
| $3.69M | 0.08% |
813,640
+92,640
| +13% | +$561K |
2020 Q3
7 quarters
|
|
67
Hyperfine
HYPR
$80M
| $3.35M | 0.08% |
1,503,754
| – | – |
2021 Q4
2 quarters
|
|
68
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $2.74M | 0.06% |
25,178
| – | – |
2021 Q2
4 quarters
|
|
|
PHAS
69
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $2.64M | 0.06% |
4,405,000
| – | – |
2021 Q1
5 quarters
|
|
|
REUN
70
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
| $2.5M | 0.06% |
595,200
| – | – |
2021 Q3
3 quarters
|
|
|
ONCS
71
DELISTED
OncoSec Medical Incorporated
ONCS
| $2.19M | 0.05% |
133,864
| – | – |
2020 Q4
6 quarters
|
|
|
OTIC
72
DELISTED
Otonomy, Inc.
OTIC
| $2.08M | 0.05% |
1,000,000
-349,905
| -26% | -$728K |
2022 Q1
1 quarter
|
|
73
ProKidney
PROK
$278M
| $1.99M | 0.05% |
200,000
| – | – |
2021 Q2
4 quarters
|
|
74
DELISTED
Akili Inc
AKLI
| $1.98M | 0.05% |
200,000
| – | – |
2021 Q2
4 quarters
|
|
75
LENZ Therapeutics
LENZ
$103M
| $1.95M | 0.04% |
101,429
| – | – |
2021 Q2
4 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q2 2022 Portfolio in Review
As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Avidity Partners Management's Q2 2022 filing shows 10 new, 31 increased, 13 reduced and 20 closed positions. Its largest new stake was Eli Lilly: 610,000 shares worth $198M. The largest sale was Merck, an estimated $194M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.
- Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
- Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
- Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
- Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
- Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
- Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
- Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.
Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.